Autolus Therapeutics

Autolus Therapeutics presents updated clinical trial data at the **American Society of Hematology (ASH) Annual Meeting 2026**. The company focuses on **T-cell therapy** advancements for hematologic malignancies. Presentations include findings from ongoing studies evaluating safety and efficacy in patients with blood cancers.

Nov 2026GlobeNewswireNews article

Autolus Therapeutics secures European marketing authorization for its CAR T therapy **AUCATZYL® (obecabtagene autoleucel)**. The treatment targets adult patients aged **26 and older** with **relapsed or refractory B-cell precursor acute lymphoblastic leukemia (R/R B-ALL)**. This approval marks a milestone for precision oncology in hematological malignancies.

Jul 2025GlobeNewswireNews article

Autolus secures EU conditional approval for **Aucatzyl**, its CAR-T cell therapy targeting a rare and aggressive form of acute lymphoblastic leukemia (ALL). The therapy represents a targeted treatment option for patients with limited alternatives. Regulatory backing follows years of clinical development in the field of cell-based cancer therapies.

May 2025pharmaphorumNews article

Autolus secures a UK licence for its cancer therapy **AUCATZYL (Obecabtagene autoleucel)**, a personalized treatment targeting adult patients aged 18 and older with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). The therapy represents a targeted approach for patients whose cancer has not responded to standard treatments. Autolus, a spinout from University College London (UCL), develops cell-based immunotherapies to address unmet needs in oncology.

Apr 2025UCL NewsNews article